FierceBiotechOriginal article
{"a":[{"_":"Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition","$":{"href":"/biotech/celldex-redeems-monoclonal-antibody-pair-phase-3-wins-chronic-skin-condition","hreflang":"en"}}]}
Phase 3positivePositive
AI Analysis
Summary
Celldex announced positive phase 3 trial results for a monoclonal antibody candidate in patients with treatment-refractory chronic spontaneous urticaria, with two trials meeting their primary endpoints.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Double phase 3 trial win
Importance:7/10
Sentiment:
0.80
Phase 3monoclonal antibodychronic spontaneous urticariaclinical trial success
Related Companies
Read the original article
Published by FierceBiotech on September 22, 2026 10:31 AM